TEM News

US IPO Market Slowly Climbs to a Two-Year High IPO activity hit a two-year high in the second quarter of 2024 but still came in below expectations, with 39 IPOs raising a combined $8.9 billion as investors continued to warm up to new issuers while remaining disciplined on valuations. A diverse group of 20 companies...read more

Just one large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading. Precision medicine company Tempus AI (TEM) priced at the high end to raise $411 million at a $6.4 billion market cap. The company’s Tempus Platform includes proprietary software and data pipelines to enable development of more...read more

Tempus AI, which provides data and analytics tools for precision medicine, raised $411 million by offering 11.1 million shares at $37, the high end of the range of $35 to $37. At pricing, the company commands a fully diluted market value of more than $6 billion. Tempus mainly generates revenue from genomic testing services, offering next-generation sequencing (NGS) diagnostics,...read more

Two sizable IPOs are scheduled for the week ahead. Precision medicine company Tempus AI (TEM) plans to raise $400 million at a $6.2 billion market cap. The company provides its Tempus Platform, which includes proprietary software and data pipelines to enable development of more personalized therapies. Highly unprofitable but growing, Tempus’ offerings have...read more